Delving into the Latest Updates on TAEST-16001 with Synapse

Overview

Basic Info

Drug Type

TCR-T Cell therapy

Synonyms

NY-ESO-1-transduced T-cells - Guangzhou-Pharmaceutical, TAEST 16001, TAEST-16001

+ [1]

Target

NY-ESO-1

Action

inhibitors

Mechanism

NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors)

Therapeutic Areas

NeoplasmsOther DiseasesRespiratory Diseases

Active Indication

Locally Advanced Soft Tissue SarcomaAdvanced Malignant Solid NeoplasmNon-Small Cell Lung Cancer+ [1]

Inactive Indication

Bladder CancerEsophageal CarcinomaLiver Cancer+ [6]

Originator Organization

Xiangxue Pharmaceutical Co., Ltd.

Active Organization

Guangdong Xiangxue Precision Medical Technology Co., Ltd.Xiangxue Life Science Technology (Guangdong) Co., Ltd.

Xiangxue Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationBreakthrough Therapy (China)

Login to view timeline

1) Primary objective To evaluate the efficacy of TAEST16001 cell therapy in patients with advanced soft tissue sarcoma whose tissue genotype is HLA-A*02:01 and whose tumor antigen NY-ESO-1 is positive, using the objective response rate (ORR) assessed by an independent imaging review committee (IRC) as the endpoint (based on Response Evaluation Criteria in Solid Tumors, version 1.1 [RECIST1.1]).

Start Date18 Jul 2022

Sponsor / Collaborator

Guangdong Xiangxue Precision Medical Technology Co., Ltd.

NCT05549921

/ RecruitingPhase 2IIT

TAEST16001 in Patients With Soft Tissue Sarcoma With Positive NY-ESO-1 Expression (Genotype: HLA-A*02:01): an Multi-center, Open-label and Single Arm Phase II Study

The main purpose of this trial is to evaluate the efficacy and safety of TAEST16001 cells in the treatment of advanced soft tissue sarcoma patients with HLA-A*02:01 tissue genotype and positive tumor antigen NY-ESO-1 expression.

Start Date08 Jul 2022

Sponsor / Collaborator

Sun Yat-Sen University

[+1]

CTR20192611

/ Active, not recruitingPhase 1

TAEST16001细胞免疫治疗以软组织肉瘤为主的晚期恶性实体瘤患者的开放式单中心安全性和有效性评价早期临床试验

[Translation] An open single-center early clinical trial evaluating the safety and efficacy of TAEST16001 cell immunotherapy in patients with advanced malignant solid tumors, mainly soft tissue sarcomas

主要目的：评价TAEST16001注射液即NY-ESO-1特异性高亲和性T细胞受体转导的自体T细胞对NY-ESO-1表达阳性复发难治性恶性实体瘤患者（以软组织肉瘤为主）的安全性和耐受性；次要目的：通过对全血TCR-T细胞的免疫及活性检测，分析TCR-T细胞在体内的存活的持续时间及在细胞中随着时间的推移的存活度。初步评价TAEST16001注射液对NY-ESO-1表达阳性恶性实体瘤的有效性。

[Translation]

The primary objective is to evaluate the safety and tolerability of TAEST16001 injection, i.e., autologous T cells transduced with NY-ESO-1-specific high-affinity T cell receptors, in patients with NY-ESO-1-positive relapsed and refractory malignant solid tumors (mainly soft tissue sarcomas). The secondary objective is to analyze the duration of TCR-T cell survival in vivo and the survival rate in cells over time through the immune and activity detection of whole blood TCR-T cells. The effectiveness of TAEST16001 injection on NY-ESO-1-positive malignant solid tumors is preliminarily evaluated.

Start Date23 Mar 2020

Sponsor / Collaborator

Guangdong Xiangxue Precision Medical Technology Co., Ltd.

100 Clinical Results associated with TAEST-16001

Login to view more data

100 Translational Medicine associated with TAEST-16001

Login to view more data

100 Patents (Medical) associated with TAEST-16001

Login to view more data

100 Deals associated with TAEST-16001

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Soft Tissue Sarcoma	Phase 2	China	Guangdong Xiangxue Precision Medical Technology Co., Ltd.	08 Jul 2022
Advanced Malignant Solid Neoplasm	Phase 1	China	Guangdong Xiangxue Precision Medical Technology Co., Ltd.	23 Mar 2020
Bladder Cancer	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017
Esophageal Carcinoma	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017
Liver Cancer	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017
Metastatic breast cancer	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017
Non-Small Cell Lung Cancer	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017
Ovarian Cancer	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017
Prostatic Cancer	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017
Soft Tissue Neoplasms	Phase 1	China	Xiangxue Pharmaceutical Co., Ltd.	14 Apr 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05549921 (TAEST16001, ASCO2024)	Phase 2	Sarcoma NY-ESO-1 \| HLA-A*02:01	8	Cyclophosphamide and fludarabine	ynmeyvyerr(ullacjlnqk) = n=7 qmrycuefem (nknwtasaab ) View more	Positive	24 May 2024
NCT04318964 (Pubmed) Manual	Phase 1	Locally Advanced Soft Tissue Sarcoma	12	TAEST16001+cyclophosphamide+fludarabine	lplcxvxket(iaqozlbojb) = ocatgngtxw ffrestvmrs (veeokhkfos ) View more	Positive	15 Aug 2023
NCT04318964 (ASCO2022) Manual	Phase 1	Locally Advanced Soft Tissue Sarcoma	12	cyclophosphamide+fludarabine+NY-ESO-1–specific TCR T-cells (TAEST16001)	nfoazorqgh(timabkmzhw) = mbtjitqnry jkavwybkzn (rxejfhelev ) View more	Positive	02 Jun 2022